RXRX
Recursion
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 1
Revenue Beats Expectation
RSI Oversold
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About RXRX
Recursion Pharmaceuticals, Inc.
A clinical-stage biotechnology company that develops technologies to enable drug discovery
Biological Technology
11/04/2013
04/16/2021
NASDAQ Stock Exchange
800
12-31
Common stock
41 S Rio Grande Street, Salt Lake City, UT 84101
--
Recursion Pharmaceuticals, Inc., was originally established on November 4, 2013 and is incorporated in Delaware. The company is a leading clinical-stage TechBio company that decodes biology to industrialize drug discovery. At the heart of the company's mission is the Recursive Operating System (OS), a platform built across multiple technologies that enables the company to map and navigate trillions of biological, chemical and patient-centric relationships in over 50 petabytes of proprietary data. The company frames this integration of physical and digital components as an iterative loop in which large-scale "wet lab" biological, chemical and patient-centric experimental data are organized by "dry lab" computing tools in order to identify, validate and translate therapeutic insights.
Company Financials
EPS
RXRX has released its 2024 Q4 earnings. EPS was reported at -0.53, versus the expected -0.42, missing expectations. The chart below visualizes how RXRX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
RXRX has released its 2024 Q4 earnings report, with revenue of 4.55M, reflecting a YoY change of -58.26%, and net profit of -178.91M, showing a YoY change of -92.38%. The Sankey diagram below clearly presents RXRX’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
